X4 PHARMACEUTICALS, INC Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals
X4 PHARMACEUTICALS, INC (XFOR) had Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals of $1.46 million as of 2018-12-31, per its 10-K filed 2019-03-11.
Discontinued › Notes › Income Taxes › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals · last filed 2019-03-11
- 2018-12-31: Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals $1.46M.
- 2017-12-31: Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals $850.00K.
- 2016-12-31: Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals $689.00K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals |
|---|---|
| 2018-12-31 | $1.46M 10-K · filed 2019-03-11 |
| 2017-12-31 | $850.00K 10-K · filed 2019-03-11 |
| 2016-12-31 | $689.00K 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |